China Insulin Industry Report, 2010
  • Jan/2011
  • Hard Copy
  • USD $1,500
  • Pages:59
  • Single User License
    (PDF Unprintable)       
  • USD $1,400
  • Code: JMH004
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $2,100
  • Hard Copy + Single User License
  • USD $1,700
      
In 2009, China’s insulin market size reached up to RMB5.3 billion, but still accounted for less than 6% of the global market. China has the world’s most diabetes patients, which is 92 million at present. In addition, the overall treatment rate of Chinese diabetes patients is less than 30%, and the per capita consumption of insulin is low, which is only about 0.8% of that of American patients. Therefore, China’s insulin market has great potential.

The insulin industry is a high-tech industry. China’s genetically engineered human insulin is still in the initial stage of industrialization, and has weak global competitiveness due to its high production cost and small production scale, which has led to the monopoly of imported insulin in China. In the first three quarters of 2010, Novo Nordisk, Eli Lilly and Sanofi-Aventis accounted for 90.6% of China’s insulin market, while Tonghua Dongbao, the largest domestic company, only accounted for 3.7%. In addition, more and more enterprises are entering the Chinese insulin market, such as The United Laboratories of Hong Kong and Bayer of Germany.

Enterprises in China’s Insulin Market by Market Share, Jan.-Sep.2010
?2011024005.gif
Source: IMS, ResearchInChina

The report not only analyzes the status quo, competition pattern and development direction of the insulin industry as a whole and its market segments, but also makes a detailed analysis of the operation and development prospect of three foreign insulin producers including Novo Nordisk, Eli Lilly and Sanofi-Aventis as well as several large-scale domestic insulin producers.

Novo Nordisk of Denmark is an insulin industry leader in both China and the world; it accounted for 83.4% of China’s recombinant human insulin market and 52.2% of China’s insulin analog market in 2008.

Eli Lilly of the United States is the second pharmaceutical giant entering in China’s insulin market. It accounted for 12.3% of China’s recombinant human insulin market and 7.7% of China’s insulin analog market in 2008; it is expanding its presence in China. It invested over USD40 million in an insulin expansion project in Suzhou in 2009.

Sanofi-Aventis of France is the world's first producer of insulin glargine analog, and accounted for 36.1% of China’s insulin analog market in 2008.

Jilin Tonghua Dongbao is China's largest producer of recombinant human insulin; in 2010, its insulin API capacity was 3,000 kg and the insulin dosage form capacity was 70 million bottles in 2010.

Beijing Gan & Lee Pharmaceutical is a company controlled by Tonghua Dongbao. Gan & Lee and Sanofi Aventis are the world’s only two insulin glargine analog manufacturers.

Jiangsu Wanbang Biopharmaceuticals is a leading animal insulin enterprise in China, and occupied more than 80% of China’s animal insulin market in 2009. In addition, its animal insulin has been selected into the national catalog of essential drugs.

1. Overview of Insulin Industry
1.1 Definition & Classification 
1.2 Industry Chain 

2. International Environment for the Operation of China’s Insulin Market 
2.1 Current Development  
2.1.1 Market Size 
2.1.2 R&D Direction of New Drugs 
2.1.3 Production Process 
2.2 Market Supply and Demand 
2.3 Competition Pattern
2.4 Development Prospect
2.4.1 Increasingly Serious Diabetes Problem
2.4.2 Competitive Drugs or Alternative Therapies 
2.4.3 Market Forecast 

3. Status Quo & Prospect of China’s Insulin Market 
3.1 Market Status 
3.2 Market Supply & Demand 
3.3 Competition Pattern
3.3.1 Foreign Monopoly 
3.3.2 Newcomers
3.4 Industry Gross Margin and Price 
3.5 Policy Environment 
3.6 Development Prospect
3.6.1 Per Capita Consumption of Insulin will Increase 
3.6.2 Market Share of Insulin will Increase 

4. Import and Export of China's Insulin Market 
4.1 Import & Export of Insulin and its Salts 
4.1.1 Export 
4.1.2 Import 
4.2 Import & Export of Insulin-containing Drugs in Unfinished Dosage Form
4.3 Import& Export of Insulin-containing Drugs in Finished Dosage Form 
4.3.1 Export
4.3.2 Import 

5. Advantageous Enterprises in China’s Insulin Production Industry 
5.1 Tonghua Dongbao 
5.1.1 Profile 
5.1.2 Operation
5.1.3 Marketing Strategy 
5.1.4 Development Trend
5.1.5 Gan & Lee Pharmaceutical 
5.2 Novo Nordisk 
5.2.1 Profile
5.2.2 Operation
5.2.3 Operation in China 
5.2.4 Development Trend
5.3 Eli Lilly 
5.3.1 Profile
5.3.2 Operation
5.3.3 Operation in China 
5.3.4 Development Trend
5.4 Sanofi-Aventis 
5.4.1 Profile 
5.4.2 Operation
5.4.3 Operation in China 
5.4.4 Development Trend 
5.5 Wanbang Biopharmaceuticals
5.5.1 Profile
5.5.2 Operation
5.5.3 Development Prospect
Types of Diabetes 
Classification and Characteristics of Insulin Dosage Forms (by Technology) 
Classification and Typical Products of Insulin Dosage Forms (by Effective Time)
Insulin Industry Chain
Global Market Scale of Diabetes Drugs and Insulin Drugs, 2008-2010
Classification of Global Diabetes Drugs, 2010
R & D of Inhaled Insulin Dosage Form, 2006-2009
Global Insulin Pump Market Scale, 2009-2016
Recombinant Human Insulin Production Carrier and its Characteristics
Global Number of Diabetes Patients, 2005-2009
Global Theoretic Demand for Insulin API, 2009
Top Three Countries by Number of Diabetes Patients, 2009 
Top Three Enterprises in Global Insulin Market, 2009
Sales of Major Producers in Global Insulin Analog Market, 2009
Drugs for the Immune Therapy of Type I Diabetes under Development, May 2010
Glucagon-like Peptide 1 (GLP-1)-related Drugs 
Insulin Cell Transplantation Research Institutions and Progress, Dec. 2010  
Global Market Scale of the Drugs for the Treatment of Type I Diabetes, 2007-2017
China’s Insulin Drug Market Scale, 2008-2009
Purchase Prices and YoY Growth of Some Insulin Products of Typical Hospitals in 22 Cities of China, 2009
Enterprises in China's Insulin Market by Market Share, Jan.-Sep. 2010
Enterprises in China’s Recombinant Human Insulin Market by Market Share, 2008
Enterprises in China's Insulin Analog Market by Market Share, 2008
Current or Potential Insulin Producers in China, 2010
Operating Gross Margin of Recombinant Human Insulin Products of Tonghua Dongbao, 2008-2010
Prices of Common Insulin Products in China, 2009-2010 
Insulin Included in the Health Insurance Directory of China, 2009
Average Insulin Utilization of Diabetes Patients by Country, 2009
Market Occupancy of China’s Insulin and Oral Hypoglycemic Drugs, 2007-2009
China’s Export Value and Prices of Insulin and its Salts, 2008-2010
China’s Export of Insulin and its Salts by Destination, Jan.-Nov. 2010
China’s Import Value and Prices of Insulin and its Salts, 2008-2010
China’s Import of Insulin and its Salts by Country of Origin, Jan.-Nov. 2010
China’s Cumulative Export Value of Insulin-containing Drugs in Unfinished Dosage Form, Jan.-Nov. 2010
China’s Export of Insulin-containing Drugs in Unfinished Dosage Form by Destination, Jan.-Nov. 2010
China’s Export Value and Prices of Insulin-containing Drugs in Finished Dosage Form, 2008-2010
China’s Export of Insulin-containing Drugs in Finished Dosage Form by Destination, Jan.-Nov. 2010
China’s Import Value and Prices of Insulin-containing Drugs in Finished Dosage Form, 2008-2010
China’s Import of Insulin-containing Drugs in Finished Dosage Form by Country of Origin, Jan.-Nov. 2010
Operating Income of Tonghua Dongbao, 2008-2010
Operating Income and Profit of Recombinant Human Insulin Products of Tonghua Dongbao, 2008-2010
Sales Expenses and YoY Growth of Tonghua Dongbao, 2008-2010
Development of Tonghua Dongbao, 2009-2010
Hospital Procurement Amount of Beijing Gan & Lee Pharmaceutical, 2008-2009
Total Operating Income and Operating Profit of Novo Nordisk, 2008-2010
Main Businesses and Products of Novo Nordisk, H1 2010
Operating Income and YoY Growth of Recombinant Human Insulin and Insulin Analog of Novo Nordisk, 2008-2010
Novo Nordisk in China, 2009
Sales Revenue of Novo Nordisk by Region, 2007-2009
Development of Novo Nordisk, 2009-2011
Major Products of Eli Lilly, 2009
Total Operating Income and Profit of Eli Lilly, 2007-2010
Operating Income of Eli Lilly by Division, 2009
Operating Income of Humulin and Humalog of Eli Lilly, 2007-2010
Eli Lilly in China, 2010
Operating Income, Operating Expenses and Profit of Eli Lilly Suzhou Pharmaceutical, 2007-2008
Development of Eli Lilly, 2008-2013
Diabetes Products of Sanofi–Aventis, 2009
Operating Income and Profit of Sanofi-Aventis, 2007-2010
Operating Income of Insulin-related Products of Sanofi-Aventis, 2008-2010
Operating Income of Insulin-related Products of Sanofi-Aventis by Region, H1 2010
Sanofi-Aventis in China, 2010
Plants of Sanofi-Aventis in China, 2010, 
Sanofi-Aventis’ Development in the Field of Insulin Products 
Profile of Jiangsu Wanbang Pharmaceuticals
Insulin Products of Jiangsu Wanbang Pharmaceuticals, 2010
Net Income of Jiangsu Wanbang Pharmaceuticals by Main Business, 2007-2010
Unit Energy Consumption of Insulin Production of Jiangsu Wanbang Pharmaceuticals, 2008-2009
Development of Jiangsu Wanbang Pharmaceuticals, 2009-2010

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

Global and China Industrial Enzyme Industry Report, 2014-2017

In recent years, the global industrial enzyme preparation market size increased year by year, registering a CAGR of 5%, approximating USD4.2178 billion in 2014. At present, the global industrial enzym...

China Blood Product Industry Report, 2015-2018

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Human Vaccine Industry Report, 2015-2018

A vaccine is a preventive biological product for human use that prevents and controls the occurrence and prevalence of infectious diseases, so the demand for such products is relatively rigid. Due to ...

China Vacuum Blood Collection Industry Report, 2014-2017

The vacuum blood collection system consisting of vacuum blood collection tubes, disposable blood collection needles, tourniquets, etc transfers human venous blood to closed containers and makes it int...

2005-2014 www.researchinchina.com All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号
在线客服系统